Download Report

Fact Sheet
Inhalation and Oral drug development experts
 Skyepharma combines proven scientific expertise with validated proprietary drug delivery
technologies to develop innovative Oral and Inhalation pharmaceutical products.
 The Group’s ideas, expertise and technologies are used by major companies around the world,
including GSK, Sanofi, Mundipharma and Kyorin.
 Revenues are generated from 16 products, eight of which have been approved and launched
in key markets in the last three years.
 With a strong balance sheet, Skyepharma is investing in new concepts, products and
technologies to drive the next phase of growth.
Oral Modified Release
Inhalation Drug Development
Skyepharma’s oral drug delivery expertise
extends from formulation to process development
and scale-up, and from technology transfer and
regulatory affairs to commercial manufacture.
These capabilities are combined with a growing
range of proprietary technologies that control
when and how orally administered drugs are
delivered into the body.
Skyepharma is a leading independent partner for
the development of inhaled products. From R&D
headquarters in Switzerland, it has proven
capabilities to develop an inhaled therapy from
early-stage concept through to regulatory
approval and product supply. The Group’s
expertise and technologies cover both Dry
Powder (DPI) and pressurised Metered Dose
(pMDI) Inhalers.
Skyepharma technologies are used in 10 oral
products marketed by leading companies in more
than 80 countries. They have helped patients
worldwide, generated more than $3 billion of
sales for our partners over the past five years and
are incorporated in some of the world’s best
known products.
Skyepharma’s researchers are working on
innovative new approaches to continue to
improve the way drugs are delivered.
Our Partners
Skyepharma and its partners recently completed
development of a unique inhaled combination
product, flutiform®, which has been approved in
35 countries. Further indications and a breathactuated version are in development.
Skyepharma’s technology has been licensed to
GSK for use in Breo® / Relvar®, Anoro® and
Incruse®. Skyepharma recently acquired a novel
inhaled therapy platform and is developing SKP2075 as a potential anti-inflammatory treatment
for COPD.
Key Contacts
Peter Grant, CEO
Andrew Derodra, CFO
Tel: +44 (0) 20 7881 0524
[email protected]
Skyepharma PLC
46-48 Grosvenor Gardens
London SW1W 0EB
www.skyepharma.com
+44 (0) 20 7881 0524
March 2015
Corporate Summary
Flexibility and resources to invest in new products,
technologies and corporate opportunities
Updated March 3 2015
LSE: SKP
Shares Outstanding: 104.8m
Market Cap: £321.8m
Year High: 373.00p
Year Low: 97.65p
Board
Peter Grant, CEO
Andrew Derodra, CFO
Non-Executive Directors:
Frank Condella, Chairman
Jean-Charles Tschudin,
Dr Thomas Werner
John Biles
Major Shareholders
Financial summary
HBM Healthcare Investments
BlackRock
Aviva Investors
Legal & General
Standard Life Investments
Analyst Coverage
N+1 Singer (Company broker)
Oriel Securities
Rx Securities
Edison
Recent announcements
Media / IR contacts
13 Feb 2015
Notice of early repayment of remainder of CRC Finance
12 Jan 2015
Pre-close update
01 Dec 2014
Kyorin launches flutiform 120-puff version
+44 (0) 7860 361746
01 Dec 2014
flutiform
[email protected]
09 Oct 2014
Interim Management Statement
Skyepharma
Jonathan Birt
®
® launch
in Spain;
Abriff ®
launch in Italy
22 Sept 2014 Notice of early repayment of Euro CRC Facility
FTI Consulting
Julia Phillips / Rob Winder /
Natalie Garland-Collins
08 Sept 2014 flutiform
21 Aug 2014
®
phase III results in paediatric asthma
+44 (0) 20 3727 1000
Half-yearly report
Skyepharma PLC
46-48 Grosvenor Gardens
London SW1W 0EB
www.skyepharma.com
+44 (0) 20 7881 0524
March 2015